



Billing Code 4410-09-M

DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
IMPORTER OF CONTROLLED SUBSTANCES
NOTICE OF APPLICATION
FISHER CLINICAL SERVICES, INC.

Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this is notice that on July 18, 2012, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of Noroxymorphone (9668), a basic class of controlled substance in schedule II.

The company plans to import the listed substance for analytical research and clinical trials.

The import of the above listed basic class of controlled substance would be granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage form for commercial distribution in the United States.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act [21 USC 952(a)(2)(B)] may, in the circumstances set forth in 21 USC 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than [INSERT DATE 30 DAYS FROM DATE OF PUBLICATION].

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required

to demonstrate to the Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration
pursuant to 21 USC 958(a); 21 USC 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: September 20, 2012

[FR Doc. 2012-24191 Filed 10/01/2012 at 8:45 am; Publication Date: 10/02/2012]